Figure 1 | Scientific Reports

Figure 1

From: Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma

Figure 1

Kaplan–Meier curves for patients treated with pembrolizumab, with and without the use of PPI or P-CAB. PPI/P-CAB users showed significantly shorter progression-free survival (A) (p < 0.001) and overall survival (B) (p = 0.031). Kaplan–Meier curves for patients treated with pembrolizumab, with or without the use of PPI or P-CAB. PPI and P-CAB users showed significantly shorter progression-free survival than non-users (C) (p = 0.001, p = 0.005, respectively). P-CAB users showed shorter overall survival than non-PPI/P-CAB users (p = 0.018). However, no difference in overall survival was noted between PPI and non-PPI/P-CAB users (D) (p = 0.126). P-CAB, potassium-competitive acid blockers; PPI, proton pump inhibitors.

Back to article page